California · Nonprofit
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (California) receives grants from 28 organizations whose IRS filings report $522,733,037 to it, the largest being Silicon Valley Community Foundation ($405,253,500). 15 of them have funded it in more than one year, and 82% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- Revenue FY2025
- $180M
- Funders on record
- 28
- Grants received
- $523M
- Net assets
- $276M
What Parker Institute for Cancer Immunotherapy does
Mission
The Parker Institute for Cancer Immunotherapy's (pici) mission is to develop and accelerate access to breakthrough cancer therapies, curating innovation from discovery to patient access.
As stated on its FY2025 Form 990.
Program
Parker Institute for Cancer Immunotherapy (pici) encourages advances in cancer immunotherapy research, collaboration, and discovery, and the translation of these advances into cures and treatments for the benefit of patients. To do this, pici partners with its consortium of preeminent hospitals and academic research centers to conduct its discovery and clinical research and provides its partners with shared research resources, such as scientific equipment, consumables, bioinformatics analysis, and a specimen biobank. Pici also funds and otherwise supports cancer immunotherapy research within its consortium.
$46,776,153 spentof which $3,623,255 as grants$1,240,750 earned by the program100% of program spending
The program described on its FY2025 Form 990. Program spending in total: $46,776,153.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2020 to 2021, from $153M to $380M (+149%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
97% of PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY’s revenue is contributions — more reliant on donations than three-quarters of its peers (1% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Karen E Knudsen Costello
CEO as of 03/2025
Board chair
Sean N Parker
Chair of the board & director
As listed on its FY2025 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 3 funders to 8 funders, grant income fell $81M → $1.3M.
11 of 28 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 82% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY leans on a few funders — its largest provides 78% of grant income and the top three 95%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
88% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY.
Largest funder’s share by year: 2017 74% · 2018 100% · 2019 84% · 2020 87% · 2021 96% · 2022 41% · 2023 59% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
40% of PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY's funders are still giving 3 years after their first grant; 54% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
82% of PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY's grant income arrives through donor-advised or pass-through sponsors, whose addresses record where the money is held rather than where the donor is. Of the $95M that is directly attributable, 64% of it comes from California funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $428M arriving through sponsors registered in 9 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY runs a healthier operating margin than three-quarters of the 1,256 health nonprofits its size.
this organization peer median middle 50% of peers· 1,256 health nonprofits over $100M, FY2025
Organizations like PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In California
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
87% of spending goes to programs.
Governance
Footprint & structure
Files a return copy in 37 states
Part of a family of 4 related entities
- Maveric LLC · disregarded
- Sean N Parker Foundation · exempt
- Economic Innovation Group Inc · exempt
- Paratope Inc · exempt
Screen this organization
A dated, signed PDF of the compliance screen for PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY?
- PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (California) receives grants from 28 organizations whose IRS filings report $522,733,037 to it, the largest being Silicon Valley Community Foundation ($405,253,500). 15 of them have funded it in more than one year, and 82% of the money arrives through donor-advised or pass-through sponsors rather than from an institution directly.
- How many funders does PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY have?
- IRS filings report 28 organizations giving $522,733,037 in grants to PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY, 15 of which have funded it in more than one year.
- Who is the largest funder of PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY?
- Silicon Valley Community Foundation is the largest funder on record, with $405,253,500 in grants. The full list of funders is on this page.
- How can an organization like PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in California. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 28 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing